The Delhi High Court has addressed critical aspects of pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents, revisiting coverage disclosure and the therapeutic efficacy threshold under Section 3(d).
Intra Cellular Therapies Case: Disclosure and Efficacy in Focus
In a significant ruling dated August 23, 2026, the Delhi High Court revisited key issues in pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents. The court examined the coverage disclosure distinction in genus-species claims alongside the therapeutic efficacy threshold imposed by Section 3(d) of the Patents Act.
The court highlighted that while certain aspects of the Section 3(d) analysis were appropriately handled, its interpretation of 'coverage' as equivalent to 'disclosure' raised concerns. Moreover, the decision’s limited engagement with novelty standards and the omission of inventive step considerations were critical critiques from legal experts.
This case carries important implications for practitioners involved in pharmaceutical patenting. It suggests a need for clearer delineation between disclosure and coverage and emphasizes a rigorous approach to evaluating therapeutic efficacy, impacting future patent applications and litigations in the sector.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026) 1 DHC 789
